IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. (Q51711886)
Jump to navigation
Jump to search
scientific article published in March 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. |
scientific article published in March 2008 |
Statements
IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis (English)
Marijn Vis
Wouter H Bos
Gertjan Wolbink
Alexandre E Voskuyl
Jos W R Twisk
Rob Van de Stadt
Dörte Hamann
Ben A C Dijkmans